Safety study of HW241045 in healthy adults
Part of Lungs & breathing clinical trials.
This is an early-stage safety and tolerability study of a new drug called HW241045 in healthy volunteers. Researchers will test the drug at different doses to understand how the body processes it and what side effects it may cause.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 45 years old
- You are in good overall health with no chronic or serious medical conditions
- You have a healthy weight: women ≥45 kg, men ≥50 kg, with BMI between 19–26
- You have no history of stomach, liver, or kidney problems that could affect how your body processes drugs
- You are not allergic to multiple substances and have no known allergy to study drug components
- You have not taken medications that interact with liver enzymes in the past 30 days
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral medication, HSK50042, for people with Idiopathic Pulmonary Fibrosis (IPF). It aims to see if the drug can help slow lung function decline, and is looking for patients who meet specific lung function criteria and are either not currently on anti-fibrotic therapy or on a stable dose.
This trial tests a new drug called SV001 to see if it is safe and tolerable for people with idiopathic pulmonary fibrosis (IPF). If you have IPF and meet certain health criteria, this study may help find new treatment options.
This trial tests a new tablet, HEC585, for people with idiopathic pulmonary fibrosis (IPF). It aims to see if the drug can help improve lung function and slow the disease. Participants must have a confirmed IPF diagnosis and meet specific breathing test results.
This Phase 2 study tests whether an oral medication (INS018_055) can help people with idiopathic pulmonary fibrosis (IPF). You may be a fit if your lung function is in a certain range and your condition is stable.
This trial tests a new drug called BC006 for people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. The goal is to see if it can help improve lung function. You may be eligible if you are 40 or older and have a confirmed IPF diagnosis with specific lung test results.
This trial tests the safety of a new drug called HW241045 in healthy volunteers. It helps doctors understand how the drug affects the body and if it causes any side effects.
Hear when a new Idiopathic Pulmonary Fibrosis (IPF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.